Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers A > Headlines for Amgen Inc. > News item |
Amgen kept at neutral by Merrill
Merrill Lynch analyst Eric Ende gave Amgen, Inc. a neutral rating on news that the District Court in Boston has denied Roche's motion to dismiss Amgen's patent infringement case concerning CERA. Now, with CERA's PDUFA date of Feb. 20, 2007 approaching, the litigation is moving ahead, according to the analyst. Roche had argued that all its CERA-related activities were protected by a certain safe harbor section of the patent code. For its part, Amgen alleges that CERA is "materially indistinguishable" from its patented EPO and that Roche's importation constitutes current infringement. Shares of the Thousand Oaks, Calif.-based biotechnology company were up 90 cents, or 1.23%, at $73.95. (Nasdaq: AMGN)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.